Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Consolidation Therapy With Immune Reconstitution Therapy (Cladribine) in Relapsing Multiple Sclerosis Patients Following a Treatment With Anti-CD20 Compounds: a Pivotal Study

NCT06854094 is registered in ClinicalTrials.gov with Ente Ospedaliero Cantonale, Bellinzona as lead sponsor.

NCT NCT06854094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06854094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Consolidation Therapy With Immune Reconstitution Therapy (Cladribine) in Relapsing Multiple Sclerosis Patients Following a Treatment With Anti-CD20 Compounds: a Pivotal Study
Lead sponsor
Ente Ospedaliero Cantonale, Bellinzona
Phase
Observational
Overall status
Active, not recruiting
Start date
October 3, 2024
Completion date
December 31, 2028
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis